Tempest Therapeutics Inc.（纳斯达克代码：TPST）今日宣布，根据提交至美国证券交易委员会（SEC）的文件显示，公司已正式任命Nicholas Rossettos为首席财务官（CFO）兼首席财务与会计官，该任命自2026年9月1日起正式生效。
这一关键人事变动标志着公司在财务管理层面迈出重要一步，旨在强化其财务领导团队并推动战略发展。SEC文件披露了上述人事调整的具体安排，确认了Rossettos的履新职责范围。此次高管变更反映了公司对治理结构和财务运营效率的持续关注。
Tempest Therapeutics Inc.（纳斯达克代码：TPST）今日宣布，根据提交至美国证券交易委员会（SEC）的文件显示，公司已正式任命Nicholas Rossettos为首席财务官（CFO）兼首席财务与会计官，该任命自2026年9月1日起正式生效。
这一关键人事变动标志着公司在财务管理层面迈出重要一步，旨在强化其财务领导团队并推动战略发展。SEC文件披露了上述人事调整的具体安排，确认了Rossettos的履新职责范围。此次高管变更反映了公司对治理结构和财务运营效率的持续关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.